Reduced-dose DOACs for management of high-risk elderly patients with AF
20 Sep 2021;
Elderly patients with atrial fibrillation (AF) remain
inadequately anticoagulated despite well documented benefits of treatment with
direct oral anticoagulants (DOACs). During a Daiichi Sankyo–sponsored webinar
at the 29th Hong Kong College of Cardiology Annual Scientific Congress, Dr
Shinya Suzuki of the Cardiovascular Institute in Tokyo, Japan, discussed the
evidence for the use of DOACs, including edoxaban, in elderly patients,
highlighting current data on the role of very-low-dose edoxaban in high-risk elderly
patients for stroke prevention without an increased risk of bleeding compared
with placebo.
Indications/Uses : In combination w/ a SSRI or SNRI for adults w/ treatment-resistant major depressive disorder, who have not responded to at least 2 different treatments w/ antidepressants in the current moderate to severe depressive episode.
Manage Account
Change Password
Sign Out
